Frontiers in Immunology

Tailored strategies for improved control of CAR-T cells in multiple myeloma

Molecular Therapy

CAR-modified marrow infiltrating lymphocytes efficiently target malignant plasma cells with very low antigen density

Frontiers in Oncology

Ocular toxicities of targeted therapies and immunotherapies in hematologic malignancies

Journal of Clinical and Experimental Hematopathology

Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma

Annals of Hematology

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study

EClinicalMedicine

Temporal trends in progression risk in smoldering myeloma: A systematic review

American Journal of Therapeutics

Global clinical trial landscape of chimeric antigen receptor T-cell therapy for multiple myeloma: Current status and future trends

Clinical Lymphoma, Myeloma & Leukemia

MRD directed consolidation in multiple myeloma-Are we there yet?

Cell Communication and Signaling

CAR-NK cell therapy in multiple myeloma: From preclinical and clinical landscape to joining the force for treatment strategies optimization

Clinical and Experimental Medicine

Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: A systematic review of monoclonal antibodies and fusion proteins in combination strategies